Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R B Thakkar

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|November 21, 2001
What do international guidelines say about therapy?R B Thakkar, S Oparil, , et al.
Current Hypertension Reports|June 26, 2001
Health outcomes associated with calcium antagonistsR B Thakkar, S Oparil
Journal of Clinical Hypertension (Greenwich, Conn.)|June 21, 2001
Primary aldosteronism: a practical approach to diagnosis and treatmentR B Thakkar, S Oparil
Current Hypertension Reports|May 17, 2001
Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugsR B Thakkar, S Oparil
Alimentary Pharmacology & Therapeutics|October 19, 2013
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERER Panaccione, J-F Colombel, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|September 19, 2015
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitisB Jharap, W J Sandborn, W Reinisch, et al.
Alimentary Pharmacology & Therapeutics|July 22, 2014
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitisD Wolf, G D'Haens, W J Sandborn, et al.
Current Medical Research and Opinion|February 27, 2013
Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's diseaseW J Sandborn, J-F Colombel, G D'Haens, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2016
Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapyJ-F Colombel, B Jharap, W J Sandborn, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|November 21, 2001
What do international guidelines say about therapy?R B Thakkar, S Oparil, , et al.
Current Hypertension Reports|June 26, 2001
Health outcomes associated with calcium antagonistsR B Thakkar, S Oparil
Journal of Clinical Hypertension (Greenwich, Conn.)|June 21, 2001
Primary aldosteronism: a practical approach to diagnosis and treatmentR B Thakkar, S Oparil
Current Hypertension Reports|May 17, 2001
Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugsR B Thakkar, S Oparil
Alimentary Pharmacology & Therapeutics|October 19, 2013
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERER Panaccione, J-F Colombel, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|September 19, 2015
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitisB Jharap, W J Sandborn, W Reinisch, et al.
Alimentary Pharmacology & Therapeutics|July 22, 2014
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitisD Wolf, G D'Haens, W J Sandborn, et al.
Current Medical Research and Opinion|February 27, 2013
Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's diseaseW J Sandborn, J-F Colombel, G D'Haens, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2016
Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapyJ-F Colombel, B Jharap, W J Sandborn, et al.
Pageof 1